1-Benzamido-1,4-dihydropyridine derivatives as anticancer agents: in vitro and in vivo assays
Resumen: 1,4-Dihydropyridine is a privileged scaffold present in many bioactive molecules, from coenzymes to commercially available drugs. Among other interesting properties, it has been found good anticancer activity in some of these 1,4-DHPs, therefore many research groups are trying to develop new compounds based on this structural core.

For this purpose, in this work, a family of 23 new 1,4-dihydropyridines has been synthesized using hydrazide and malononitrile derivatives as precursors. This straightforward catalytic process has given rise to the desired products with moderate to excellent yields. All the compounds have been tested against four different cancer cell lines [HeLa (human cervical carcinoma), Jurkat (leukemia), A549 (human lung cancer) and MIA PaCa-2 (pancreatic cancer)] to establish a preliminary structure–activity relationship. From this study, and among the best candidates, we chose 4-chlorophenyl and 4-(trifluoromethyl)phenyl derivatives in the malononitrile ring to synthesize a second generation of molecules with enhanced cytotoxicity, modifying the substituent in the N-heterocyclic position (acylhydrazine moieties). With this second generation of compounds, we successfully decreased the IC50 until 7 µM.

An in-depth analysis of their biological properties suggests that these promising compounds trigger a non-conventional cell death mechanism known as paraptosis. Moreover, the tested photophysical properties of these products show in some cases an interesting long wavelength emission and excitation, potentially leading to new biosensors or theragnostic agents.

Finally, in vivo assays concerning the acute toxicity in mice of two of the most active compounds (with an alkyl chain of seven carbon atoms in the acylhydrazine moiety) demonstrated that even dosed at thousands fold the corresponding IC50 values (2500 and 3300 times more concentrated than the IC50 values for the two compounds studied), there was no sign of harmful effects on the tested subjects, results that support their use in further studies to discover new anticancer drugs.

Idioma: Inglés
DOI: 10.1016/j.arabjc.2022.104514
Año: 2023
Publicado en: ARABIAN JOURNAL OF CHEMISTRY 16, 2 (2023), 104514 [22 pp.]
ISSN: 1878-5352

Factor impacto JCR: 5.3 (2023)
Categ. JCR: CHEMISTRY, MULTIDISCIPLINARY rank: 65 / 230 = 0.283 (2023) - Q2 - T1
Factor impacto CITESCORE: 10.8 - Chemistry (all) (Q1) - Chemical Engineering (all) (Q1)

Factor impacto SCIMAGO: 0.864 - Chemistry (miscellaneous) (Q1) - Chemical Engineering (miscellaneous) (Q1)

Financiación: info:eu-repo/grantAgreement/ES/DGA/E07-20R
Financiación: info:eu-repo/grantAgreement/ES/AEI/PID2019-104379RB-C21
Financiación: info:eu-repo/grantAgreement/ES/AEI/PID2020-117455GB-I00
Financiación: info:eu-repo/grantAgreement/ES/DGA/B31-20R
Financiación: info:eu-repo/grantAgreement/ES/MICINN-AEI/RED2018-102471-T
Financiación: info:eu-repo/grantAgreement/ES/MICINN/RTI2018-097836-J-I00
Financiación: info:eu-repo/grantAgreement/ES/MICINN/RYC-2018-025872-I
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Química Inorgánica (Dpto. Química Inorgánica)
Área (Departamento): Área Química Orgánica (Dpto. Química Orgánica)
Área (Departamento): Área Biología Celular (Dpto. Bioq.Biolog.Mol. Celular)


Creative Commons Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.


Exportado de SIDERAL (2024-07-31-09:45:22)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos



 Registro creado el 2023-03-13, última modificación el 2024-07-31


Versión publicada:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)